Compare Stocks: IKT, AMPH, PCRX, and SPTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$26.62 +3.1%	$23.14	$16.65 ▼ $29.52	$1.13B	0.9	558,134 shs	437,694 shs
IKT Inhibikase Therapeutics	$1.97 +3.1%	$2.30	$1.33 ▼ $2.61	$274.89M	0.89	601,261 shs	435,034 shs
PCRX Pacira BioSciences	$36.31 -0.2%	$25.56	$18.80 ▼ $36.46	$1.45B	0.25	1.97 million shs	4.69 million shs
SPTX Seaport Therapeutics	$18.15 +1.3%	$22.44	$14.85 ▼ $28.38	$971.59M	N/A	321,952 shs	171,206 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+4.68%	+13.08%	+42.20%	+2.46%
IKT Inhibikase Therapeutics	0.00%	-1.50%	-15.45%	-3.43%	+18.67%
PCRX Pacira BioSciences	0.00%	+44.03%	+44.32%	+42.50%	+55.10%
SPTX Seaport Therapeutics	0.00%	-1.47%	-22.04%	-15.89%	+1,814,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$26.62 +3.1%	$23.14	$16.65 ▼ $29.52	$1.13B	0.9	558,134 shs	437,694 shs
IKT Inhibikase Therapeutics	$1.97 +3.1%	$2.30	$1.33 ▼ $2.61	$274.89M	0.89	601,261 shs	435,034 shs
PCRX Pacira BioSciences	$36.31 -0.2%	$25.56	$18.80 ▼ $36.46	$1.45B	0.25	1.97 million shs	4.69 million shs
SPTX Seaport Therapeutics	$18.15 +1.3%	$22.44	$14.85 ▼ $28.38	$971.59M	N/A	321,952 shs	171,206 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+4.68%	+13.08%	+42.20%	+2.46%
IKT Inhibikase Therapeutics	0.00%	-1.50%	-15.45%	-3.43%	+18.67%
PCRX Pacira BioSciences	0.00%	+44.03%	+44.32%	+42.50%	+55.10%
SPTX Seaport Therapeutics	0.00%	-1.47%	-22.04%	-15.89%	+1,814,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-15.48% Downside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	174.11% Upside
PCRX Pacira BioSciences	2.00	Hold	$33.33	-8.20% Downside
SPTX Seaport Therapeutics	2.67	Moderate Buy	$38.57	112.51% Upside

Current Analyst Ratings Breakdown

Latest IKT, AMPH, PCRX, and SPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$31.00 ➝ $36.50
10/9/2026	PCRX Pacira BioSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$25.00 ➝ $36.50
10/9/2026	PCRX Pacira BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$38.00 ➝ $36.50
10/8/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
10/8/2026	SPTX Seaport Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/8/2026	PCRX Pacira BioSciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$36.50
10/8/2026	PCRX Pacira BioSciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$36.00
10/8/2026	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
10/8/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
10/7/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $31.00
10/5/2026	PCRX Pacira BioSciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.57	$4.25 per share	6.26	$17.17 per share	1.55
IKT Inhibikase Therapeutics	$260K	1,057.28	N/A	N/A	$2.30 per share	0.86
PCRX Pacira BioSciences	$726.41M	1.99	$3.86 per share	9.41	$16.11 per share	2.25
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	15.75	10.28	5.13	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
PCRX Pacira BioSciences	$7.03M	$0.35	103.75	15.32	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)
SPTX Seaport Therapeutics	-$74.88M	-$12.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IKT, AMPH, PCRX, and SPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AMPH Amphastar Pharmaceuticals	$0.8640	N/A	N/A	N/A	$197.85 million	N/A
11/5/2026	Q3 2026	PCRX Pacira BioSciences	$0.7320	N/A	N/A	N/A	$182.87 million	N/A
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
IKT Inhibikase Therapeutics	N/A	15.82	15.82
PCRX Pacira BioSciences	0.54	5.04	3.94
SPTX Seaport Therapeutics	N/A	18.00	18.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
IKT Inhibikase Therapeutics	3.81%
PCRX Pacira BioSciences	99.73%
SPTX Seaport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
IKT Inhibikase Therapeutics	7.10%
PCRX Pacira BioSciences	6.40%
SPTX Seaport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
PCRX Pacira BioSciences	829	39.86 million	37.31 million	Optionable
SPTX Seaport Therapeutics	58	53.53 million	N/A	N/A

IKT, AMPH, PCRX, and SPTX Headlines

Recent News About These Companies

Seaport Therapeutics Inc SPTX

October 11 at 8:24 AM | morningstar.comM

Seaport Therapeutics, Inc. Presents Phase 1 Clinical Data for Glyphago At the 39Th European College of Neuropsychopharmacology Congress

October 10 at 9:32 AM | marketscreener.comM

Seaport Therapeutics Says Drug Potentially Reduces Liver Impact of Depression Treatment

October 9 at 11:30 PM | marketscreener.comM

Seaport reports 6.8-fold GlyphAgo bioavailability increase

October 9 at 8:27 AM | grafa.comG

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

October 9 at 8:27 AM | finance.yahoo.com

Seaport Therapeutics Announces First Patient Dosed in Phase 2A Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder and Sleep Disturbance

October 8 at 5:19 PM | marketscreener.comM

Seaport Therapeutics (NASDAQ:SPTX) Stock Rating Reaffirmed as Buy by HC Wainwright

October 8 at 8:05 AM | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Up 3.6% - Here's Why

October 7, 2026 | marketbeat.com

Seaport Therapeutics doses first patient in Phase 2a GAD trial

October 7, 2026 | grafa.comG

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

October 7, 2026 | marketscreener.comM

Seaport Therapeutics Doses First Patient in Phase 2a GlyphAgo Trial

October 7, 2026 | finance.yahoo.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Down 6% - Here's Why

October 6, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up - What's Next?

October 1, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Down - Here's What Happened

September 30, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 6.3% - Here's What Happened

September 28, 2026 | marketbeat.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57

September 28, 2026 | marketbeat.com

Seaport Therapeutics, Inc. $SPTX Shares Newly Acquired by State Street Corp

September 27, 2026 | marketbeat.com

Seaport Therapeutics, Inc. : Raymond James réitère son opinion positive sur le titre

September 26, 2026 | zonebourse.comZ

Raymond James initiates coverage of Seaport Therapeutics at strong buy

September 26, 2026 | msn.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Lifted to "Strong-Buy" by Raymond James Financial

September 26, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up - Here's Why

September 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, AMPH, PCRX, and SPTX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$26.62 +0.81 (+3.14%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$26.64 +0.02 (+0.06%)

As of 10/9/2026 07:30 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Inhibikase Therapeutics NASDAQ:IKT

$1.97 +0.06 (+3.14%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.25%)

As of 10/9/2026 07:30 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Pacira BioSciences NASDAQ:PCRX

$36.31 -0.08 (-0.22%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$36.18 -0.13 (-0.37%)

As of 10/9/2026 08:00 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Seaport Therapeutics NASDAQ:SPTX

$18.15 +0.24 (+1.34%)

As of 10/9/2026 04:00 PM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, AMPH, PCRX, and SPTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, AMPH, PCRX, and SPTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, AMPH, PCRX, and SPTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, AMPH, PCRX, and SPTX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Inhibikase Therapeutics NASDAQ:IKT

Pacira BioSciences NASDAQ:PCRX

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, AMPH, PCRX, and SPTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, AMPH, PCRX, and SPTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, AMPH, PCRX, and SPTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, AMPH, PCRX, and SPTX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Inhibikase Therapeutics NASDAQ:IKT

Pacira BioSciences NASDAQ:PCRX

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools